Novo Nordisk A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novo Nordisk A/S
Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
Emerging Company Profile: Backed by investors including Novo Holdings, HealthCap and RA Capital Management, Hemab Therapeutics is bringing together strong technology and deep expertise to ‘leapfrog’ treatment for several rare bleeding and thrombosis disorders into the 21st century.
US FDA’s first decision on biosimilars interchangeability might have less meaning for two insulin products, but payer and prescriber responses to interchangeable biosimilars for adalimumab, which are further out on the horizon, may be more instructive regarding the importance of interchangeability status.
- Large Molecule
- Other Names / Subsidiaries
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd